Sumatriptan transdermal system can be correctly assembled and applied during migraine attacks.

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Clinical Usability Studies

Background:

• Iontophoresis offers noninvasive drug delivery via low electrical current.
• Sumatriptan TDS delivers a pre-programmed dose transdermally without skin disruption.
• Ease of use during a disabling migraine attack is crucial for patient confidence.

Purpose of the Study:

• To validate the ease of assembly and application of sumatriptan iontophoretic transdermal system (TDS) during migraine attacks.
• To assess usability among migraineurs and healthcare professionals (HCPs).

Main Methods:

• A single-center, open-label human factor use study.
• Evaluated three groups: trained migraineurs, untrained migraineurs, and untrained HCPs.
• Usability rated on a 1-7 scale (1=difficult, 7=easy).

Main Results:

• 100% successful assembly and application in both preliminary (16/16) and final (48/48) testing.
• Mean ease of assembly score: 6.1; mean ease of application score: 6.8.
• High success rates observed even in migraineurs experiencing moderate to severe attacks.

Conclusions:

• Sumatriptan TDS demonstrates 100% successful assembly and application during mild to severe migraine attacks.
• High usability ratings (assembly: 6.1, application: 6.8) indicate patient and HCP confidence.
• Patients and HCPs can be assured of readily assembling and using sumatriptan TDS during a migraine attack.